source
- Attovia Therapeutics raises $289 million in IPO to fund anti-itch drug developmentAttovia Therapeutics completed an initial public offering that generated $289 million in gross proceeds. The company sold 17 million shares at $17 each, exceeding its original target of $182.4 mill…
- Sanofi pauses phase 2 bronchiectasis trial of SAR445399 for strategic reasonsSanofi has halted a phase 2 study of its monoclonal antibody SAR445399 in adults with non‑cystic fibrosis bronchiectasis. The trial, which began in April, was a randomized, double‑blind, placebo‑co…